Clinical trials update from the European Society of Cardiology-Heart Failure meeting 2015: AUGMENT-HF, TITRATION, STOP-HF, HARMONIZE, LION HEART, MOOD-HF, and renin-angiotensin inhibitors in patients with heart and renal failure

European Journal of Heart Failure

Volumn 17, Issue 9, 2015, Pages 979-983

  Pellicori, Pierpaolo ^a   Clark, Andrew L ^a  

^a CASTLE HILL HOSPITAL   (United Kingdom)

Author keywords

Clinical trials; Heart failure

Indexed keywords

ALGINIC ACID; AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; CALCIUM; LEVOSIMENDAN; PLACEBO; POTASSIUM; SACUBITRIL PLUS VALSARTAN; SODIUM ZIRCONIUM CYCLOSILICATE; STROMAL CELL DERIVED FACTOR 1; ANGIOTENSIN RECEPTOR ANTAGONIST;

CARDIOVASCULAR RISK; DISEASE SEVERITY; DRUG EFFECT; DRUG SAFETY; DRUG TOLERABILITY; HEART FAILURE; HEART LEFT VENTRICLE EJECTION FRACTION; HUMAN; HYDROGEL; KIDNEY FAILURE; MAINTENANCE THERAPY; MORTALITY; POTASSIUM BLOOD LEVEL; PRIORITY JOURNAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; SURVIVAL RATE; SURVIVAL TIME; CARDIOLOGY; COMPLICATION; DRUG EFFECTS; MEDICAL SOCIETY; ORGANIZATION; RENAL INSUFFICIENCY; SPAIN;

ANGIOTENSIN RECEPTOR ANTAGONISTS; CARDIOLOGY; CONGRESSES AS TOPIC; HEART FAILURE; HUMANS; RENAL INSUFFICIENCY; RENIN-ANGIOTENSIN SYSTEM; SOCIETIES, MEDICAL; SPAIN;

EID: 84941802611     PISSN: 13889842     EISSN: 18790844     Source Type: Journal    
DOI: 10.1002/ejhf.340     Document Type: Review

References (19)

1. McMurray JJ, Packer M, Desai AS, Gong J, Lefkowitz MP, Rizkala AR, Rouleau JL, Shi VC, Solomon SD, Swedberg K, Zile MR,; PARADIGM-HF Investigators and Committees. Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med 2014; 371: 993-1004.
2. Clark AL, Pellicori P,. Clinical trials update from the European Society of Cardiology meeting 2014: PARADIGM-HF, CONFIRM-HF, SIGNIFY, atrial fibrillation, beta-blockers and heart failure, and vagal stimulation in heart failure. ESC Heart Failure 2014; 1: 82-86.
3. McMurray JJ, Packer M, Desai AS, Gong J, Lefkowitz MP, Rizkala AR, Rouleau J, Shi VC, Solomon SD, Swedberg K, Zile MR,; PARADIGM-HF Committees and Investigators. Dual angiotensin receptor and neprilysin inhibition as an alternative to angiotensin-converting enzyme inhibition in patients with chronic systolic heart failure: rationale for and design of the Prospective comparison of ARNI with ACEI to Determine Impact on Global Mortality and morbidity in Heart Failure trial (PARADIGM-HF). Eur J Heart Fail 2013; 15: 1062-1073.
4. McMurray JJ, Adamopoulos S, Anker SD, Auricchio A, Bohm M, Dickstein K, Falk V, Filippatos G, Fonseca C, Gomez-Sanchez MA, Jaarsma T, Kober L, Lip GY, Maggioni AP, Parkhomenko A, Pieske BM, Popescu BA, Ronnevik PK, Rutten FH, Schwitter J, Seferovic P, Stepinska J, Trindade PT, Voors AA, Zannad F, Zeiher A, Bax JJ, Baumgartner H, Ceconi C, Dean V, Deaton C, Fagard R, Funck-Brentano C, Hasdai D, Hoes A, Kirchhof P, Knuuti J, Kolh P, McDonagh T, Moulin C, Reiner Z, Sechtem U, Sirnes PA, Tendera M, Torbicki A, Vahanian A, Windecker S, Bonet LA, Avraamides P, Ben Lamin HA, Brignole M, Coca A, Cowburn P, Dargie H, Elliott P, Flachskampf FA, Guida GF, Hardman S, Iung B, Merkely B, Mueller C, Nanas JN, Nielsen OW, Orn S, Parissis JT, Ponikowski P,. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail 2012; 14: 803-869.
5. Jonsson A, Edner M, Alehagen U, Dahlström U,. Heart failure registry: a valuable tool for improving the management of patients with heart failure. Eur J Heart Fail 2010; 12: 25-31.
6. Cleland JG, Carubelli V, Castiello T, Yassin A, Pellicori P, Antony R,. Renal dysfunction in acute and chronic heart failure: prevalence, incidence and prognosis. Heart Fail Rev 2012; 17: 133-149.
7. de Silva R, Nikitin NP, Witte KK, Rigby AS, Goode K, Bhandari S, Clark AL, Cleland JG,. Incidence of renal dysfunction over 6 months in patients with chronic heart failure due to left ventricular systolic dysfunction: contributing factors and relationship to prognosis. Eur Heart J 2006; 27: 569-581.
8. Kiernan MS, Wentworth D, Francis G, Martinez FA, Dickstein K, Komajda M, Zannad F, Neaton JD, Konstam MA,. Predicting adverse events during angiotensin receptor blocker treatment in heart failure: results from the HEAAL trial. Eur J Heart Fail 2012; 14: 1401-1409.
9. Michel A, Martin-Perez M, Ruigomez A, Garcia Rodriguez LA,. Risk factors for hyperkalaemia in a cohort of patients with newly diagnosed heart failure: a nested case-control study in UK general practice. Eur J Heart Fail 2015; 17: 205-213.
10. Packham DK, Rasmussen HS, Lavin PT, El-Shahawy MA, Roger SD, Block G, Qunibi W, Pergola P, Singh B,. Sodium zirconium cyclosilicate in hyperkalemia. N Engl J Med 2015; 372: 222-231.
11. Kosiborod M, Rasmussen HS, Lavin P, Qunibi WY, Spinowitz B, Packham D, Roger SD, Yang A, Lerma E, Singh B,. Effect of sodium zirconium cyclosilicate on potassium lowering for 28 days among outpatients with hyperkalemia: the HARMONIZE randomized clinical trial. JAMA 2014; 312: 2223-2233.
12. Anker SD, Kosiborod M, Zannad F, Piña IL, McCullough PA, Filippatos G, van der Meer P, Ponikowski P, Rasmussen HS, Lavin PT, Singh B, Yang A, Deedwania P,. Maintenance of serum potassium with sodium zirconium cyclosilicate (ZS-9) in heart failure patients: results from a phase III randomized, double-blind, placebo-controlled trial. Eur J Heart Fail 2015; 17: XXX-XXX.
13. Sabbah HN, Wang M, Gupta RC, Rastogi S, Ilsar I, Sabbah MS, Kohli S, Helgerson S, Lee RJ,. Augmentation of left ventricular wall thickness with alginate hydrogel implants improves left ventricular function and prevents progressive remodeling in dogs with chronic heart failure. JACC Heart Fail 2013; 1: 252-258.
14. Lee LC, Wall ST, Klepach D, Ge L, Zhang Z, Lee RJ, Hinson A, Gorman JH 3rd, Gorman RC, Guccione JM,. Algisyl-LVR™ with coronary artery bypass grafting reduces left ventricular wall stress and improves function in the failing human heart. Int J Cardiol 2013; 168: 2022-2028.
15. Askari AT, Unzek S, Popovic ZB, Goldman CK, Forudi F, Kiedrowski M, Rovner A, Ellis SG, Thomas JD, DiCorleto PE, Topol EJ, Penn MS,. Effect of stromal-cell-derived factor 1 on stem-cell homing and tissue regeneration in ischaemic cardiomyopathy. Lancet 2003; 362: 697-703.
16. Lee BC, Hsu HC, Tseng WY, Chen CY, Lin HJ, Ho YL, Su MJ, Chen MF,. Cell therapy generates a favourable chemokine gradient for stem cell recruitment into the infarcted heart in rabbits. Eur J Heart Fail 2009; 11: 238-245.
17. Macchia A, Monte S, Pellegrini F, Romero M, D'Ettorre A, Tavazzi L, Tognoni G, Maggioni AP,. Depression worsens outcomes in elderly patients with heart failure: an analysis of 48 117 patients in a community setting. Eur J Heart Fail 2008; 10: 714-721.
18. Jünger J, Schellberg D, Müller-Tasch T, Raupp G, Zugck C, Haunstetter A, Zipfel S, Herzog W, Haass M,. Depression increasingly predicts mortality in the course of congestive heart failure. Eur J Heart Fail 2005; 7: 261-267.
19. O'Connor CM, Jiang W, Kuchibhatla M, Silva SG, Cuffe MS, Callwood DD, Zakhary B, Stough WG, Arias RM, Rivelli SK, Krishnan R,; SADHART-CHF Investigators. Safety and efficacy of sertraline for depression in patients with heart failure: results of the SADHART-CHF (Sertraline Against Depression and Heart Disease in Chronic Heart Failure) trial. J Am Coll Cardiol 2010; 56: 692-699.